Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 9/20 | 0.55 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.49 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24384569 | 1.00 | KCNH2 (0.55) | KCNH2TLR7TLR8CYP2D6 | |
| SCHEMBL22958983 | 0.91 | KCNH2 (0.56) | KCNH2TLR7TLR8CYP2D6 | |
| SCHEMBL22819395 | 0.86 | KCNH2 (0.39) | KCNH2TLR7TLR8CYP2D6 | |
| SCHEMBL29601605 | 0.86 | KCNH2 (0.39) | KCNH2TLR7TLR8CYP2D6 | |
| SCHEMBL21325598 | 0.83 | TLR8 (0.69) | KCNH2TLR7TLR8CYP2D6 | |
| SCHEMBL24719004 | 0.83 | TLR8 (0.69) | KCNH2TLR7TLR8CYP2D6 | |
| SCHEMBL22825664 | 0.78 | CA2 (0.36) | KCNH2TLR7TLR8 | |
| SCHEMBL28691699 | 0.77 | CYP2D6 (0.65) | KCNH2TLR7TLR8CYP2D6 | |
| SCHEMBL21325603 | 0.77 | CYP2D6 (0.65) | KCNH2TLR7TLR8CYP2D6 | |
| SCHEMBL13975896 | 0.77 | CYP2D6 (0.65) | KCNH2TLR7TLR8CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278964-A1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2023-09-07 | — | — | US | disclosed |
| US-20230278964-A1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2023-09-07 | — | — | US | disclosed |
| EP-4059924-A1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2022-09-21 | — | — | EP | disclosed |
| US-20210040046-A1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF | Janssen Sciences Ireland Unlimi (IE) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040046-A1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF | HRH4, HRH3, HNMT | KCNH2 968/4885TLR7 52/4885TLR8 400/4885 |
| US-20230278964-A1 | 2,4-DIAMINOQUINAZOLINE DERIVATIVES AND MEDICAL USES THEREOF | QDPR, PADI2, PEPD | KCNH2 1977/4885TLR7 728/4885TLR8 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.